Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Administered as a '5 Days on-2 Days Off' Oral Treatment in Advanced Ovarian Cancer.
Latest Information Update: 16 Jul 2015
At a glance
- Drugs Rubitecan (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 19 Sep 2005 New trial record.